Oral BRX011 for advanced dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests an oral medication called BRX011 taken once daily for geographic atrophy, a progressive form of advanced dry age-related macular degeneration. The goal is to see if it is safe and can help slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 55 years of age or older
- Have geographic atrophy (a form of advanced dry age-related macular degeneration) in one eye
- Have some remaining vision (able to read at least 20/200 on an eye chart) with a noticeable sensitivity to dim light
- Have no current or past wet (neovascular) age-related macular degeneration in the study eye
- Not have taken omega-3 supplements (like fish oil) in the 4 weeks before starting, and avoid them during the trial
- Female participants must no longer be able to get pregnant (for example, due to age or surgery)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial tests an investigational treatment called PST-611 for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and may slow the progression of the disease.
This trial tests a new nerve stimulation treatment for people with geographic atrophy, a form of advanced dry age-related macular degeneration. It aims to see if this treatment can help preserve or improve vision.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.